Skip to main content
Premium Trial:

Request an Annual Quote

Vermillion Completes Acquisition of Correlogic Ovarian Cancer Dx Business

NEW YORK (GenomeWeb News) – Vermillion today said that it has completed the acquisition of the assets associated with Correlogic Systems' ovarian cancer diagnostics business for $435,000 in cash.

Vermillion said early last month that it had acquired the assets of Correlogic, a firm operating under Chapter 11 bankruptcy protection.

According to Austin, Texas-based Vermillion, the assets include more than 1,000 prospectively collected diagnostic samples from ovarian tumor studies, three biomarker-related US patents that are pending, software, and other intellectual property. The firm plans to use the assets in advancing its ovarian cancer testing franchise, including in the development of its OVA2 next-generation test.

"While Vermillion notes the loss of a substantial competitor, the acquisition of these assets will enhance our development efforts, and offers significant savings in terms of time and cost," Vermillion CEO Gail Page said in a statement.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.